

Drug Deal Disclosure Act

High drug costs put vital medicines out of reach for vast numbers of Americans. In 2025, 33 percent of adults reported avoiding filling a prescription, opting for an over-the-counter alternative, cutting their pills in half, or skipping doses of medicine due to cost.¹ Democrats' *Inflation Reduction Act* delivered meaningful, durable reforms, capping seniors' out-of-pocket costs each year, allowing Medicare to negotiate prices, and penalizing manufacturers that spike prices faster than inflation.

Trump claims his Administration is lowering prescription drug costs through a series of so-called "deals" with drug manufacturers—**but the details of the "deals" are shrouded in secrecy**. On July 31, 2025, the Trump Administration sent letters² to 17 pharmaceutical companies demanding that they enter into voluntary agreements to utilize what the Trump Administration refers to as "Most-Favored-Nation" (MFN) pricing. The Commerce Secretary has also been negotiating with pharma companies to exclude them from Trump's tariffs in exchange for vague promises to onshore production—essentially, giving them sweetheart tax breaks.³

Sixteen pharmaceutical companies have since entered into secret, temporary agreements with the Trump Administration.⁴ Many CEOs stood alongside Trump in the Oval Office touting the value these "deals" would bring as their companies' stock prices rose. But the Trump Administration refuses to disclose the specific terms and commitments of these "deals," going so far as to impose strict confidentiality agreements on manufacturers, effectively denying the public basic information about these agreements. Congressional oversight attempts have been met with little cooperation both from the Administration and from manufacturers.

The Drug Deal Disclosure Act, introduced by Ranking Member Wyden and Senators Welch, Warren, Gallego, Merkley, Luján, Baldwin, Whitehouse, Kelly, Sanders, Warner, Smith, Hassan, Cortez Masto, Bennet, Warnock, Hirono, and Cantwell, would compel the release of the deals struck between the Trump Administration and pharmaceutical manufacturers, generating answers for the American people as to whether or not these agreements will meaningfully lower their drug prices.

The Drug Deal Disclosure Act:

- Requires the Secretary of Health and Human Services (HHS) to release the details of the above-described deals struck between drug manufacturers and the Trump Administration.
- Obligates the Secretary of HHS to create a report to Congress listing all documents and information released and withheld shortly after releasing these agreements.
- Instructs the Congressional Budget Office and the Government Accountability Office to co-author and publish a comprehensive analysis of the economic and budgetary impacts of all disclosed agreements so that the American people can confidently assess the extent to which these deals save patients and taxpayers money.

¹ [Americans' Challenges with Health Care Costs | KFF](#)

² [Fact Sheet: President Donald J. Trump Announces Actions to Get Americans the Best Prices in the World for Prescription Drugs – The White House](#)

³ [Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States – The White House](#)

⁴ [Global Pharma Companies that Have Publicly Announced Trump Drug Pricing Agreements](#)